Harrow Health, Inc. (HROW): Price and Financial Metrics


Harrow Health, Inc. (HROW): $6.15

-0.74 (-10.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HROW POWR Grades


  • HROW scores best on the Quality dimension, with a Quality rank ahead of 60.71% of US stocks.
  • The strongest trend for HROW is in Stability, which has been heading up over the past 179 days.
  • HROW ranks lowest in Growth; there it ranks in the 4th percentile.

HROW Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for HROW is 6.42 -- better than 94.76% of US stocks.
  • With a year-over-year growth in debt of 231.26%, Harrow Health Inc's debt growth rate surpasses 95.06% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Harrow Health Inc is reporting a growth rate of 1,013.52%; that's higher than 97.73% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Harrow Health Inc are QUOT, TWOU, SWI, ASPN, and SILK.
  • HROW's SEC filings can be seen here. And to visit Harrow Health Inc's official web site, go to www.harrowinc.com.

HROW Valuation Summary

  • HROW's price/earnings ratio is 40.4; this is 10.68% higher than that of the median Healthcare stock.
  • HROW's price/sales ratio has moved NA NA over the prior 151 months.
  • HROW's price/earnings ratio has moved up 43.4 over the prior 151 months.

Below are key valuation metrics over time for HROW.

Stock Date P/S P/B P/E EV/EBIT
HROW 2021-08-31 4.6 12.3 40.4 27.4
HROW 2021-08-30 4.3 11.5 37.8 25.7
HROW 2021-08-27 4.1 10.9 36.0 24.4
HROW 2021-08-26 4.0 10.8 35.6 24.2
HROW 2021-08-25 4.1 11.0 36.1 24.5
HROW 2021-08-24 4.1 11.1 36.4 24.7

HROW Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at 116.8%.
  • The 2 year price growth rate now stands at 82.85%.
  • The 5 year net income to common stockholders growth rate now stands at -39.27%.
Over the past 52 months, HROW's revenue has gone up $47,246,000.

The table below shows HROW's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 72.476 5.082 -18.479
2021-09-30 66.883 6.006 -9.912
2021-06-30 62.571 10.749 7.054
2021-03-31 52.497 2.658 9.767
2020-12-31 48.871 -1.1 -3.357
2020-09-30 46.88 1.118 -1.849

HROW's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HROW has a Quality Grade of B, ranking ahead of 89.94% of graded US stocks.
  • HROW's asset turnover comes in at 0.893 -- ranking 26th of 682 Pharmaceutical Products stocks.
  • CGEN, ADAP, and ACOR are the stocks whose asset turnover ratios are most correlated with HROW.

The table below shows HROW's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.893 0.747 0.148
2021-03-31 0.943 0.722 0.201
2020-12-31 0.917 0.704 -0.020
2020-09-30 0.873 0.699 0.005
2020-06-30 0.861 0.680 -0.359
2020-03-31 0.898 0.675 -0.374

HROW Price Target

For more insight on analysts targets of HROW, see our HROW price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.13 Average Broker Recommendation 1.38 (Strong Buy)

HROW Stock Price Chart Interactive Chart >

Price chart for HROW

HROW Price/Volume Stats

Current price $6.15 52-week high $12.99
Prev. close $6.89 52-week low $5.40
Day low $6.10 Volume 242,300
Day high $6.93 Avg. volume 92,331
50-day MA $6.71 Dividend yield N/A
200-day MA $8.53 Market Cap 166.24M

Harrow Health, Inc. (HROW) Company Bio


Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.


HROW Latest News Stream


Event/Time News Detail
Loading, please wait...

HROW Latest Social Stream


Loading social stream, please wait...

View Full HROW Social Stream

Latest HROW News From Around the Web

Below are the latest news stories about Harrow Health Inc that investors may wish to consider to help them evaluate HROW as an investment opportunity.

Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022

NASHVILLE, Tenn., February 24, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to d

Yahoo | February 24, 2022

Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100

NASHVILLE, Tenn., February 22, 2022--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, the Company’s drug candidate for ocular surface anesthesia and intraoperative pain management during ocular surgery. The FDA has assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of October 16, 2022.

Yahoo | February 22, 2022

Harrow Health to Present at Aegis Virtual Conference

NASHVILLE, Tenn., February 15, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 23-25, 2022.

Yahoo | February 15, 2022

Two Insider Moonshots Rising on Sudden Buying

Biotech insiders are among the most important investors to pay close attention to.

Thomas Yeung on InvestorPlace | February 10, 2022

Harrow Health Publishes Corporate Transparency Report

NASHVILLE, Tenn., February 08, 2022--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company’s website, harrowinc.com. The report focuses on Harrow Health’s commitment to initiatives that it believes support its mission to make innovative, sight-saving medications more accessible and affordable.

Yahoo | February 8, 2022

Read More 'HROW' Stories Here

HROW Price Returns

1-mo -6.68%
3-mo -22.64%
6-mo -40.12%
1-year -34.71%
3-year -1.76%
5-year 84.13%
YTD -28.82%
2021 25.95%
2020 -11.83%
2019 36.73%
2018 234.71%
2017 -32.00%

Continue Researching HROW

Here are a few links from around the web to help you further your research on Harrow Health Inc's stock as an investment opportunity:

Harrow Health Inc (HROW) Stock Price | Nasdaq
Harrow Health Inc (HROW) Stock Quote, History and News - Yahoo Finance
Harrow Health Inc (HROW) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8426 seconds.